Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gain Therapeutics Inc (NQ: GANX ) 1.050 +0.010 (+0.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Gain Therapeutics Inc < Previous 1 2 Next > Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 June 28, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO June 27, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease June 27, 2024 Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference June 25, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M June 18, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Gain Therapeutics Announces Pricing of $11.0 Million Public Offering June 13, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Proposed Public Offering June 13, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 May 30, 2024 New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s disease From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update May 14, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease April 24, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer April 08, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer April 01, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update March 26, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics to Present at Public Ventures Discovery Day March 15, 2024 Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb... From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease March 05, 2024 Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease February 27, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight February 14, 2024 Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST From Gain Therapeutics, Inc. Via GlobeNewswire UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease February 06, 2024 Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease February 06, 2024 Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update January 31, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024 January 02, 2024 Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research December 04, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model December 01, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics to Participate in AI Driven Drug Discovery Summit November 29, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option November 24, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants November 21, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Proposed Public Offering November 20, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update November 14, 2023 Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease October 04, 2023 First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023 September 25, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.